أعرض في EDS

278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients

التفاصيل البيبلوغرافية
العنوان: 278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients
المؤلفون: R Roylance, B. Krastev, Wenli Tao, Richard D. Baird, M. Maglakelidze, H-T. Arkenau, A. Crijanovschi, Jessica A. Sorrentino, C. Murias, I. Bulat, Ruhi Rai, Andrew P. Beelen, Andrew M Wardley, M. Gogiladze
المصدر: Annals of Oncology. 31:S351-S352
بيانات النشر: Elsevier BV, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Fulvestrant, business.industry, Advanced breast, Cancer, Hematology, medicine.disease, Phase i ii, Internal medicine, medicine, business, medicine.drug
تدمد: 0923-7534
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5122265f68d5a8eb7ef03b44a2592ee5Test
https://doi.org/10.1016/j.annonc.2020.08.380Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........5122265f68d5a8eb7ef03b44a2592ee5
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534